PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques

Launched by RUIJIN HOSPITAL · Jan 21, 2025

Keywords

ClinConnect Summary

The clinical trial titled "PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging Techniques" is studying how certain factors affect the progression of heart disease, specifically coronary artery disease (CAD). Researchers will follow patients for up to five years, conducting a special heart scan called coronary CTA after two years to see how the condition of their arteries changes. They will look closely at the structure and function of any plaque (fatty deposits) in the arteries, as well as how medications and other health factors might influence heart health and the risk of serious heart-related events.

To participate, individuals must be at least 18 years old and have symptoms of heart disease, or be suspected of having CAD with visible plaque in the major arteries. However, some people may not be eligible, such as those with certain health conditions, recent heart procedures, or serious illnesses. Participants can expect regular follow-ups and detailed assessments of their heart health throughout the study. This trial aims to enhance understanding of heart disease progression and improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Clinically significant angina pectoris, or suspected CAD
• • Receive coronary CTA scan, with a visible plaque (defined as ≥25% diameter stenosis) in major coronary arteries.
• Exclusion Criteria:
• • Unsuitable for coronary CTA (such as severe renal impairment, uncontrolled thyroid condition, allergic to iodine, etc.)
• • Receive percutaneous coronary intervention (PCI) within 6 months
• • Prior history of myocardial infarction or heart failure
• • Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
• • Abnormal liver function (serum alanine aminotransferase \[ALT\] level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR ≤30 ml/min)
• • Familial hypercholesterolemia
• • Estimated survival ≤ 1 year
• • Malignant tumor
• • Pregnant or lactation, or have the intention to give birth within one year
• • Poor coordinance, unable to follow-up